Journal of Cancer Research and Therapeutics Close
 

Figure 2: Kaplan–Meier curves for the weekly high-dose 5-FU and continuous venous infusion groups. (a) Overall survival curve. There was no significant difference between the two groups (log-rank test, P = 0.146). (b) Recurrence-free survival (RFS) curve. The continuous venous infusion group had a significantly better RFS rate (log-rank test, P = 0.038). (c) Liver-specific RFS curve. Continuous venous infusion tended to show a protective effect against liver metastasis (log-rank P = 0.077). CVI = Continuous vein infusion, WHF = Weekly high-dose 5-fluorouracil

Figure 2: Kaplan–Meier curves for the weekly high-dose 5-FU and continuous venous infusion groups. (a) Overall survival curve. There was no significant difference between the two groups (log-rank test, <i>P</i> = 0.146). (b) Recurrence-free survival (RFS) curve. The continuous venous infusion group had a significantly better RFS rate (log-rank test, <i>P</i> = 0.038). (c) Liver-specific RFS curve. Continuous venous infusion tended to show a protective effect against liver metastasis (log-rank <i>P</i> = 0.077). CVI = Continuous vein infusion, WHF = Weekly high-dose 5-fluorouracil